Your browser doesn't support javascript.
loading
Expresión de CD44 HCAM en el carcinoma subseroso de la vesícula biliar / CD44 HCAM expression in subserous gallbladder carcinoma
Roa Esterio, Iván; Villaseca H., Miguel Angel; Araya Oróstica, Juan Carlos; Roa S., Juan Carlos; De Aretxabala Urquiza, Xabier; Ibacache S., Gilda; García V., Marcela.
  • Roa Esterio, Iván; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • Villaseca H., Miguel Angel; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • Araya Oróstica, Juan Carlos; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • Roa S., Juan Carlos; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • De Aretxabala Urquiza, Xabier; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • Ibacache S., Gilda; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
  • García V., Marcela; Universidad de la Frontera. Facultad de Medicina. Departamento de Cirugía.
Rev. méd. Chile ; 129(7): 727-734, jul. 2001. ilus, tab, graf
Article in Spanish | LILACS | ID: lil-300037
ABSTRACT

Background:

HCAM or CD44 is a multifunctional cell adhesion molecule, related to cell-cell, cell-extracellular matrix interactions and involved in tumor invasion.

Aim:

To study the importance of CD44 expression in subserous gallbladder carcinoma. Material and

methods:

One hundred five samples (93 female) of subserous gallbladder carcinoma and 33 non tumoral gallbladder were studied. CD44 was stained using the streptavidine-biotin technique, using human anti CD44 antibodies. Eighty subjects with carcinoma were followed for a period up to 105 months.

Results:

Mean age of patients was 62,6 years old, all tumors were adenocarcinoma, all were silent and 13 percent were well differentiated. CD44 was expressed in all controls and in 91 percent, the expression was normal. In 57 percent of cancer samples, CD44 expression was abnormal, in 50 percent it was less expressed and in 24 percent, it was not expressed. No differences in CD44 expression was observed between mucosa from control samples and mucosa adjacent to the tumor or superficial or deep tumoral areas. Global five years survival was 40 percent. No significant differences in survival were observed in those tumors with a lower of absent CD44 expression. Six patients with a higher expression died before 18 months of follow up.

Conclusions:

Nearly 50 percent of subserous gallbladder carcinomas show an abnormal CD44 expression
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Adenocarcinoma / Gallbladder Neoplasms Limits: Adult / Female / Humans / Male Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2001 Type: Article / Project document Affiliation country: Chile

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Adenocarcinoma / Gallbladder Neoplasms Limits: Adult / Female / Humans / Male Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2001 Type: Article / Project document Affiliation country: Chile